LITTLE ELM, Texas–(BUSINESS WIRE)–Retractable Technologies, Inc. (NYSE American: RVP) reports the following information relating to the year ended December 31, 2024. Further details concerning the results of operations as well as other matters are available in Retractable’s Form 10-K filed on March 28, 2025 with the U.S. Securities and Exchange Commission. The Company’s revenues for … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “HIV Drugs – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for HIV Drugs was valued at US$32.8 Billion in 2024 and is projected to reach US$44.5 Billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Anesthesia Devices – A Global Market Overview” report has been added to ResearchAndMarkets.com’s offering. The global anesthesia devices market is estimated to be valued at US$17.1 billion in 2024, and is projected to reach US$27.3 billion by 2030, registering a CAGR of 8.1% from 2024 to 2030. The global anesthesia devices market is … [Read more…]
BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company“), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under … [Read more…]
Manufacturers of food equipment materials, nonfood compounds and chemicals can now certify their products to NSF’s PFAS-Free guideline, demonstrating a commitment to human and planet health. AUCKLAND, New Zealand–(BUSINESS WIRE)–NSF, a leading global public health and safety organization, today announced the launch of NSF Certification Guideline 537: PFAS-Free Products for Nonfood Compounds and Food Equipment … [Read more…]
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with … [Read more…]
TOKYO & KAGOSHIMA, Japan & SEATTLE–(BUSINESS WIRE)–Tokyo & Kagoshima, Japan (March 28, 2025 JST) / Seattle, Washington, USA (March 27, 2025 PT): Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Chairman, President & CEO: Ryoichi Nagata, M.D., Ph.D.; hereinafter “SNBL”) and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions … [Read more…]
CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the seventh consecutive year and is ranked number 26 out of the top 100 companies for 2025. “Being recognized as one of Barron’s … [Read more…]
Cleerly to Present Late-Breaking Findings and Participate in Key ACC.25 Sessions DENVER–(BUSINESS WIRE)–#AI—Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial … [Read more…]
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 28, 2025 NASHVILLE, Tenn.–(BUSINESS WIRE)–$HROW–Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after … [Read more…]
